Samuel T. Wilkinson

Samuel T. Wilkinson

Auto-generated profile, based on publicly available information

Samuel T. Wilkinson

Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in American Journal of Psychiatry
Verified
Journal Article
Closed access
SWSamuel T. Wilkinson
Samuel T. Wilkinson
EBElizabeth D. Ballard
Elizabeth D. Ballard
MBMichael H. Bloch
Michael H. Bloch
SMSanjay J. Mathew
Sanjay J. Mathew
JMJames W. Murrough
James W. Murrough
GSGerard Sanacora
Gerard Sanacora

14 January 2016 in Annual Review of Medicine
Verified
Journal Article
Closed access
SWSamuel T. Wilkinson
Samuel T. Wilkinson
SYStephanie Yarnell
Stephanie Yarnell
RRRajiv Radhakrishnan
Rajiv Radhakrishnan
SBSamuel A. Ball
Samuel A. Ball
DDDeepak Cyril D'SOuza
Deepak Cyril D'SOuza
Marijuana is becoming legal in an increasing number of states for both medical and recreational use. Considerable controversy exists regarding the public health impact of these changes. The evidence for the legitimate medical use of marijuana or cannabinoids is limited to a few indications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and spasticity in multiple sclerosis. Although cannabinoids show therapeutic promise in other areas, robust clinical evidence is still lacking. The relationship between legalization and prevalence is still unknown. Although states where marijuana use is legal have higher rates of use than nonlegal states, these higher rates were generally found even prior to legalization. As states continue to proceed with legalization for both medical and recreational use, certain public health issues have become increasingly relevant, including the effects of acute marijuana intoxication on driving abilities, unintentional ingestion of marijuana pro...


23 September 2015 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
SWSamuel T. Wilkinson
Samuel T. Wilkinson
ESElina Stefanovics
Elina Stefanovics
RRRobert A. Rosenheck
Robert A. Rosenheck
An increasing number of states have approved posttraumatic stress disorder (PTSD) as a qualifying condition for medical marijuana, although little evidence exists evaluating the effect of marijuana use in PTSD. We examined the association between marijuana use and PTSD symptom severity in a longitudinal, observational study. From 1992 to 2011, veterans with DSM-III/-IV PTSD (N = 2,276) were admitted to specialized Veterans Affairs treatment programs, with assessments conducted at intake and 4 months after discharge. Subjects were classified into 4 groups according to marijuana use: those with no use at admission or after discharge ("never-users"), those who used at admission but not after discharge ("stoppers"), those who used at admission and after discharge ("continuing users"), and those using after discharge but not at admission ("starters"). Analyses of variance compared baseline characteristics and identified relevant covariates. Analyses of covariance then compared groups on follow-up measures of PTSD symptoms, drug and alcohol use, violent behavior, and employment. After we adjusted for relevant baseline covariates, marijuana use was significantly associated with worse outcomes in PTSD symptom severity (P < .01), violent behavior (P < .01), and measures of alcohol and drug use (P < .01) when compared with stoppers and never-users. At follow-up, stoppers and never-users had the lowest levels of PTSD symptoms (P < .0001), and starters had the highest levels of violent behavior (P < .0001). After adjusting for covariates and using never-users as a reference, starting marijuana use had an effect size on PTSD symptoms of +0.34 (Cohen d = change/SD), and stopping marijuana use had an effect size of -0.18. In this observational study, initiating marijuana use after treatment was associated with worse PTSD symptoms, more violent behavior, and alcohol use. Marijuana may actually worsen PTSD symptoms or nullify the benefits of specialized, intensive treatment. Cessation or prevention of use may be an important goal of treatment.

19 April 2022 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
SNSina Nikayin
Sina Nikayin
EMEva Murphy
Eva Murphy
JKJohn H. Krystal
John H. Krystal
SWSamuel T. Wilkinson
Samuel T. Wilkinson
Ketamine is an NMDA receptor antagonist that can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resi...

11 May 2017 in Psychotherapy and Psychosomatics
Verified
Journal Article
Open access
PDF file
SWSamuel T. Wilkinson
Samuel T. Wilkinson
DWDaShaun Wright
DaShaun Wright
MFMadonna K. Fasula
Madonna K. Fasula
LFLisa Fenton
Lisa Fenton
MGMatthew Griepp
Matthew Griepp
GSGerard Sanacora
Gerard Sanacora
Introduction: Ketamine has shown rapid though short-lived antidepressant effects. The possibility of concerning neurobiological changes following repeated exposure to the drug motivates the development of strategies that obviate or minimize the need for longer-term treatment with ketamine. In this open-label trial, we investigated whether cognitive behavioral therapy (CBT) can sustain or extend ketamine's antidepressant effects. Methods: Patients who were pursuing ketamine infusion therapy for treatment-resistant depression were invited to participate in the study. If enrolled, the subjects initiated a 12-session, 10-week course of CBT concurrently with a short 4-treatment, 2-week course of intravenous ketamine (0.5 mg/kg infused over 40 min) provided under a standardized clinical protocol. Results: Sixteen participants initiated the protocol, with 8 (50%) attaining a response to the ketamine and 7 (43.8%) achieving remission during the first 2 weeks of protocol. Among ketamine responders, the relapse rate at the end of the CBT course (8 weeks following the last ketamine exposure) was 25% (2/8). On longer-term follow-up, 5 of 8 subjects eventually relapsed, the median time to relapse being 12 weeks following ketamine exposure. Among ketamine remitters, 3 of 7 retained remission until at least 4 weeks following the last ketamine exposure, with 2 retaining remission through 8 weeks following ketamine exposure. Ketamine nonresponders did not appear to benefit from CBT. Conclusions: CBT may sustain the antidepressant effects of ketamine in treatment-resistant depression. Well-powered randomized controlled trials are warranted to further investigate this treatment combination as a way to sustain ketamine's antidepressant effects.